Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709281 | 0.77 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8274815 | 0.76 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8274820 | 0.76 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16031250 | 0.76 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1703014 | 0.74 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13068592 | 0.73 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15834913 | 0.71 | CYP2D6 (0.51) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL31548529 | 0.71 | CYP2D6 (0.51) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13593032 | 0.71 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27017167 | 0.69 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970195-B1 | PROCESSES FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9481708-B2 | Process for producing Sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481708-B2 | Process for producing Sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150322109-A1 | NOVEL PROCESS FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322109-A1 | NOVEL PROCESS FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-9115175-B2 | Processes for Producing sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115175-B2 | Processes for Producing sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2014152928-A2 | NOVEL PROCESSES FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275480-A1 | NOVEL PROCESSES FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275480-A1 | NOVEL PROCESSES FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322109-A1 | NOVEL PROCESS FOR PRODUCING SOVAPREVIR | FDPS, WEE1, CYP3A4 | CYP2D6 60/4885HDAC3 4147/4885HDAC1 3368/4885 |
| US-20140275480-A1 | NOVEL PROCESSES FOR PRODUCING SOVAPREVIR | FDPS, WEE1, CYP3A4 | CYP2D6 45/4885HDAC3 4113/4885HDAC1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.